Cresco Labs Logo
CA22587M1068
A2PAHM
CL.CN

Cresco Labs

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 4,99 € (+1.060,47 %). Medianen er 4,99 € (+1.060,47 %).

Køb
  4
Behold
  3
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Cresco Labs strengthens presence in Pennsylvania with purchase of PharmaCann for $50 million

    Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » Mere på de.investing.com


  • Cresco Labs beats Q2 expectations, but stock remains under pressure

    Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » Mere på de.investing.com


  • Cresco Labs: analysts expect smaller quarterly loss on declining revenue on May 8

    Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » Mere på finanzen.net


  • Cresco Labs launches at-the-market stock program for around US$100 million

    Cresco Labs has established an at-the-market (ATM) program to permit the sale of subordinate voting shares totaling up to approximately US$100 million. A distribution agreement has been entered with Haywood Securities; no shares have been issued yet. Net proceeds are intended primarily for general corporate purposes and potential acquisitions. Sales will occur on the Canadian Securities Exchange and are not registered for a U.S. public offering. » Mere på de.investing.com


  • Cresco Labs sells California business as part of strategic realignment

    Cresco Labs has announced the sale of its operations in California to strengthen its balance sheet and cash flow, and to focus on higher-margin core markets. CEO Charlie Bachtell cited structural challenges and price pressure in the California market as reasons for the withdrawal. Analysts see uncertain short-term growth prospects, while the company continues to distribute its premium brand FloraCal in the US. » Mere på de.investing.com

I 2022 har Cresco Labs allerede udloddet 26,30 € i udbytte. Den seneste udlodning fandt sted i januar 2022.

Virksomhedstal

I det seneste kvartal havde Cresco Labs en omsætning på 152,54 mio. € og et nettoresultat på -10,98 mio. €
(EUR) september 2026
YoY
Omsætning 152,54 mio. 8,55 %
Bruttofortjeneste 70,17 mio. 3,77 %
Nettoresultat -10,98 mio. 24,42 %
EBITDA 9,14 mio. 46,04 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
156,67 mio. €
Antal aktier
361,07 mio.
Højeste/laveste i 52 uger
2,09 € - 0,42 €
Udbytte Nej
Beta
1,72
P/E (PE Ratio)
-1,67
PEG (PEG Ratio)
0,01
K/I (PB Ratio)
0,51
P/S (PS Ratio)
0,26

Virksomhedsprofil

Cresco Labs Inc. og dets datterselskaber dyrker, fremstiller og sælger cannabisprodukter til detail- og medicinsk brug i USA. Selskabet leverer cannabis i form af blomster, vapepenne, live resins, engangspenne og ekstrakter under Cresco-mærket; vape-patroner, vapepenne, blomster, popcorn, shake, pre-rolls, shorties og koncentrater under High Supply-mærket; vapes og gummibolcher under Good News-mærket; vapes og spiselige produkter under Wonder Wellness Co-mærket; samt tinkturer, kapsler, salver og sublinguale olier under Remedi-mærket, og cannabisprodukter under Reserve-mærket. Selskabet tilbyder også cannabisblomster under FloraCal-mærket; og chokolade- og toffeekonfekture, frugtbaserede gummibolcher, hårde bolcher og taffy under Mindy's Edibles-mærket, og licenserer desuden Kiva-mærket, som producerer cannabisinfunderede spiseligheder, herunder chokoladekonfekture, gummibolcher, mints og tarts. Derudover tilbyder selskabet cannabisinfunderede spiseligheder under Sunnyside-mærket. Pr. 27. januar 2022 ejede og drev det 48 dispensarer. Selskabet blev stiftet i 1990 og har hovedkontor i Chicago, Illinois.

Navn
Cresco Labs
CEO
Charles Bachtell
Hjemsted Chicago, il
USA
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
03.12.2018
Medarbejdere 2.900

Tickersymboler

Børs Symbol
Cnq
CL.CN
Pnk
CRLBF
Frankfurt
6CQ.F
Düsseldorf
6CQ.DU
München
6CQ.MU
🍪

Parqet  bruger cookies. Læs mere